Targeting α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy

Rita Citraro, Rossana Aiello, Valentina Franco, Giovambattista De Sarro, Emilio Russo

Research output: Contribution to journalArticle

Abstract

Introduction: Despite epilepsies being between the oldest and most studied neurological diseases, new treatment remains an unmet need of scientific research due to the high percentage of refractory patients. Several studies have identified new suitable anti-seizure targets. Glutamate activation of α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors (AMPARs) have long ago been identified as suitable targets for the development of anti seizure drugs. Areas covered: Here, we describe: i) AMPARs' structure and their involvement and role during seizures and in epilepsy and ii) the efficacy of AMPAR antagonists in preclinical models of seizures and epilepsy. Expert opinion: The physiological and pathological role of AMPAR in the CNS and the development of AMPAR antagonists have recently gained attention considering their recent involvement in status epilepticus and the marketing of perampanel. The need for new anti-seizure drugs represents a major challenge in both preclinical and clinical epilepsy. The introduction into the market of perampanel for the treatment of epilepsy will shed new light on the real potential of AMPAR antagonism in clinical settings outside the limited world of clinical trials. While research will go on in this area, fundamental will be the post-marketing evaluation of perampanel efficacy and tolerability and a better definition of the role of this receptor in the epileptic brain.

Original languageEnglish
Pages (from-to)319-334
Number of pages16
JournalExpert Opinion on Therapeutic Targets
Volume18
Issue number3
DOIs
Publication statusPublished - Mar 2014

Fingerprint

Isoxazoles
Propionates
Hydroxyl Radical
Epilepsy
Seizures
Marketing
Status Epilepticus
Expert Testimony
Research
Pharmaceutical Preparations
Refractory materials
Glutamic Acid
Brain
Chemical activation
Clinical Trials
Therapeutics
perampanel

Keywords

  • AMPA antagonists
  • Auxiliary proteins
  • IKM
  • NS1209
  • Perampanel
  • Seizures

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Targeting α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy. / Citraro, Rita; Aiello, Rossana; Franco, Valentina; De Sarro, Giovambattista; Russo, Emilio.

In: Expert Opinion on Therapeutic Targets, Vol. 18, No. 3, 03.2014, p. 319-334.

Research output: Contribution to journalArticle

Citraro, Rita ; Aiello, Rossana ; Franco, Valentina ; De Sarro, Giovambattista ; Russo, Emilio. / Targeting α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy. In: Expert Opinion on Therapeutic Targets. 2014 ; Vol. 18, No. 3. pp. 319-334.
@article{841290d7fa5e42c6ac7ac689814ecd92,
title = "Targeting α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy",
abstract = "Introduction: Despite epilepsies being between the oldest and most studied neurological diseases, new treatment remains an unmet need of scientific research due to the high percentage of refractory patients. Several studies have identified new suitable anti-seizure targets. Glutamate activation of α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors (AMPARs) have long ago been identified as suitable targets for the development of anti seizure drugs. Areas covered: Here, we describe: i) AMPARs' structure and their involvement and role during seizures and in epilepsy and ii) the efficacy of AMPAR antagonists in preclinical models of seizures and epilepsy. Expert opinion: The physiological and pathological role of AMPAR in the CNS and the development of AMPAR antagonists have recently gained attention considering their recent involvement in status epilepticus and the marketing of perampanel. The need for new anti-seizure drugs represents a major challenge in both preclinical and clinical epilepsy. The introduction into the market of perampanel for the treatment of epilepsy will shed new light on the real potential of AMPAR antagonism in clinical settings outside the limited world of clinical trials. While research will go on in this area, fundamental will be the post-marketing evaluation of perampanel efficacy and tolerability and a better definition of the role of this receptor in the epileptic brain.",
keywords = "AMPA antagonists, Auxiliary proteins, IKM, NS1209, Perampanel, Seizures",
author = "Rita Citraro and Rossana Aiello and Valentina Franco and {De Sarro}, Giovambattista and Emilio Russo",
year = "2014",
month = "3",
doi = "10.1517/14728222.2014.874416",
language = "English",
volume = "18",
pages = "319--334",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Targeting α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy

AU - Citraro, Rita

AU - Aiello, Rossana

AU - Franco, Valentina

AU - De Sarro, Giovambattista

AU - Russo, Emilio

PY - 2014/3

Y1 - 2014/3

N2 - Introduction: Despite epilepsies being between the oldest and most studied neurological diseases, new treatment remains an unmet need of scientific research due to the high percentage of refractory patients. Several studies have identified new suitable anti-seizure targets. Glutamate activation of α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors (AMPARs) have long ago been identified as suitable targets for the development of anti seizure drugs. Areas covered: Here, we describe: i) AMPARs' structure and their involvement and role during seizures and in epilepsy and ii) the efficacy of AMPAR antagonists in preclinical models of seizures and epilepsy. Expert opinion: The physiological and pathological role of AMPAR in the CNS and the development of AMPAR antagonists have recently gained attention considering their recent involvement in status epilepticus and the marketing of perampanel. The need for new anti-seizure drugs represents a major challenge in both preclinical and clinical epilepsy. The introduction into the market of perampanel for the treatment of epilepsy will shed new light on the real potential of AMPAR antagonism in clinical settings outside the limited world of clinical trials. While research will go on in this area, fundamental will be the post-marketing evaluation of perampanel efficacy and tolerability and a better definition of the role of this receptor in the epileptic brain.

AB - Introduction: Despite epilepsies being between the oldest and most studied neurological diseases, new treatment remains an unmet need of scientific research due to the high percentage of refractory patients. Several studies have identified new suitable anti-seizure targets. Glutamate activation of α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors (AMPARs) have long ago been identified as suitable targets for the development of anti seizure drugs. Areas covered: Here, we describe: i) AMPARs' structure and their involvement and role during seizures and in epilepsy and ii) the efficacy of AMPAR antagonists in preclinical models of seizures and epilepsy. Expert opinion: The physiological and pathological role of AMPAR in the CNS and the development of AMPAR antagonists have recently gained attention considering their recent involvement in status epilepticus and the marketing of perampanel. The need for new anti-seizure drugs represents a major challenge in both preclinical and clinical epilepsy. The introduction into the market of perampanel for the treatment of epilepsy will shed new light on the real potential of AMPAR antagonism in clinical settings outside the limited world of clinical trials. While research will go on in this area, fundamental will be the post-marketing evaluation of perampanel efficacy and tolerability and a better definition of the role of this receptor in the epileptic brain.

KW - AMPA antagonists

KW - Auxiliary proteins

KW - IKM

KW - NS1209

KW - Perampanel

KW - Seizures

UR - http://www.scopus.com/inward/record.url?scp=84894195297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894195297&partnerID=8YFLogxK

U2 - 10.1517/14728222.2014.874416

DO - 10.1517/14728222.2014.874416

M3 - Article

C2 - 24387310

AN - SCOPUS:84894195297

VL - 18

SP - 319

EP - 334

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 3

ER -